CD163 and melanoma: Our data from the spatial analysis showed that immunosuppressive markers like CD163, CD209, and PDL1 were upregulated in the SLN (+) and SLN (−) of melanoma patients, which were mostly expressed on myeloid cells (Figure 4A).